Nolvadex Articles
UK Scientists Slam Early Closure Of Tamoxifen Trial
9 April 1998
Stock Commentary New York
8 April 1998
Stock Commentary Europe
8 April 1998
Zeneca Allays Fears Of Near-Term Product Gap
4 December 1997
Greek Govt Adjusts Prices Of 6,009 Drugs
3 October 1997
1st Approval For Novartis' Exelon; 2nd For Revasc
7 August 1997
USA Clears Fareston For Breast Cancer
9 June 1997
Chemo Plus Tamoxifen More Effective
30 May 1997
Zeneca Fights Off Tamoxifen Challenge
21 April 1997
European And London Stock Comment
21 April 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Ciba Launches Femara And Diovan In The UK
2 December 1996
Tamoxifen Beyond Five Years; No Added Benefit
18 November 1996
Strong Fundamentals On Show At Zeneca
19 August 1996
"Excellent" 1st Half For Zeneca But Share Price Falls
12 August 1996
First Approval Of Ciba's Femara In France
5 August 1996
US Corporate Quarterly Results Round-Up
13 May 1996
Zeneca Wins Tamoxifen Patent Challenge
6 May 1996
Barr Mounts Challenge To US Patents For Prozac
22 April 1996
EMEA Approves Roche's CellCept
26 February 1996
Zeneca Takes Charge, But Still At Forecasts' Top-End
29 January 1996
Zeneca Pipeline Part II: Exploratory Targets
8 January 1996
Five-Year Cut-Off For Tamoxifen Treatment?
4 December 1995
Isepalline Launched In First European Market
30 October 1995
Zeneca's Arimidex Launched In First Market
25 September 1995
Results US Biopharmaceutical Firms Progress In Second Quarter
4 September 1995
Alfacell's Onconase Set To Start Phase III Testing
21 August 1995
Zeneca's Pharma Sales Go Over L1 Billion
7 August 1995
Tamoxifen Improvement
24 April 1995
Zeneca Submits UK Arimidex Application
10 April 1995
20 Leading US Drugs' Price Increases Slammed
27 March 1995
US Difficulties For Zeneca In 1994
6 March 1995
Clinical Results With Zeneca's ICI 182780
16 January 1995
Pfizer's Fruitful Product Pipeline
7 November 1994
Zeneca Submits SNDA In USA For Zoladex
12 September 1994
Zeneca Praises 1st Half Underlying Growth
8 August 1994
ZENECA PLANS CHINESE VENTURES
4 July 1994
TAMOXIFEN STUDY RESTARTS IN USA
13 June 1994
CONGRESS SLAMS CANCER DATA FRAUD
25 April 1994
TAMOXIFEN LABEL CHANGE IN USA
18 April 1994
ZENECA'S PIPELINE ON TARGET AS TENORMIN SLIPS
14 March 1994
"SUCCESS" IN FIRST YEAR FOR ZENECA
7 March 1994
NET PROFITS LEAP AT SUMITOMO PHARMA
7 March 1994
VALIDITY OF TAMOXIFEN PROPHYLAXIS QUESTIONED
28 February 1994
BETTER SECOND HALF FOR ZENECA
31 January 1994
ZOLADEX LAUNCHED IN JAPAN FOR BREAST CANCER
31 January 1994
BARR'S 4th QTR AIDED BY PATENT OUTCOME
11 October 1993
ZENECA SURPRISES WITH STRONG PHARMA GROWTH
9 August 1993
ZENECA MAKES GOOD ADVANCES IN 1st HALF
2 August 1993
PROPHYLACTIC TAMOXIFEN TRIAL
26 July 1993
NOLVADEX US OK FOR MALE BREAST CANCER
26 July 1993
CANCER MEDICINES IN DEVELOPMENT
14 June 1993
THREE-WAY GENERIC AGREEMENT
31 May 1993
TAIHO TRIAL NEWS
26 April 1993
BREAST CANCER US RESEARCH UPDATE
26 April 1993
ZENECA REPORTS ANTICANCER SUCCESSES
19 April 1993
ZENECA SETTLES US PATENT DISPUTE
22 March 1993
TENORMIN DRAGS DOWN ZENECA AS IT DEMERGES
8 March 1993
NOLVADEX IN RETROPERITONEAL FIBROSIS
22 February 1993
WORLD ANTICANCER/ IMMUNOLOGY MARKET
8 February 1993
ZENECA'S PROMISING R&D PIPELINE PRESENTED
14 December 1992
ICI AT "BREAKING POINT" WITH DEMERGER
14 December 1992
US TAMOXIFEN STUDY DOUBTS: NIH RESPONDS
2 November 1992
TURKISH JV FOR ICI
12 October 1992
BARR AND FDA ON COLLISION COURSE
22 June 1992
WIDESPREAD IGNORANCE ABOUT HRT IN UK
18 May 1992
US COURT OVERTURNS NOLVADEX PATENT
4 May 1992
TAMOXIFEN OF BENEFIT IN OSTEOPOROSIS?
6 April 1992
TAMOXIFEN OF BENEFIT IN OSTEOPOROSIS?
6 April 1992
TAMOXIFEN TRIAL IN MEN
16 March 1992
ICI, UPJOHN TO DROP SUMITOMO JVs
20 January 1992
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
